Long-term effectiveness of fremanezumab in episodic and chronic migraine patients in clinical routine – 24-months results from the prospective non-interventional FINESSE study
Andreas Straube, Gregor Broessner, Charly Gaul, Xenia Hamann, Axel Heinze, Torsten Kraya, Lars Neeb · 2025
Read Long-term effectiveness of fremanezumab in episodic and chronic migraine patients in clinical routine – 24-months results from the prospective non-interventional FINESSE study by Andreas Straube, Gregor Broessner, Charly Gaul, Xenia Hamann, Axel Heinze, Torsten Kraya, Lars Neeb (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12837042.txt.
Description
Straube and six co-authors report two-year results for the migraine drug fremanezumab in routine care, in a 2025 paper. The drug blocks the CGRP pathway and prevents migraine in adults with frequent attacks. Long-term data from daily practice have been scarce.
The FINESSE study followed more than a thousand patients in Germany and Austria. About half reached at least a halving of monthly migraine days in the first six months. Gains in migraine days, use of acute drugs, severity, and disability scores held over two years. No new safety concerns appeared. The authors say the real-world results match the good profile seen in trials.
Catalog record
| CREATOR | Andreas Straube, Gregor Broessner, Charly Gaul, Xenia Hamann, Axel Heinze, Torsten Kraya, Lars Neeb |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |